Physician profile
Michael Schiano
NPI 1245246933
$1,953.71
in general payments reported to CMS, 2019-2025
26 companies · $277 in 2025
The $277 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $401 · 2020: $136 · 2021: $486 · 2022: $247 · 2023: $157 · 2024: $249 · 2025: $277.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $684.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $683.77 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $411.46 | 2021-2025 | |
| Novo Nordisk INC | $197.77 | 2019-2025 | Ozempic, Rybelsus |
| Gilead Sciences, INC. | $171.55 | 2019 | |
| Astrazeneca Pharmaceuticals LP | $165.49 | 2021-2023 | Farxiga |
| Lilly USA, LLC | $131.26 | 2021-2025 | Mounjaro, Zepbound, Jardiance |
| Glaxosmithkline, LLC. | $114.52 | 2019-2022 | |
| Avanir Pharmaceuticals, INC. | $98.85 | 2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $80.72 | 2019-2025 | Jardiance, Tradjenta, Synjardy |
| Sumitomo Pharma America, INC. | $74.14 | 2025 | Myfembree, Gemtesa |
| Merck Sharp & Dohme LLC | $71.76 | 2019-2023 | Steglatro, Belsomra |
| Acadia Pharmaceuticals INC | $51.55 | 2022 | |
| Ibsa Pharma INC. | $47.27 | 2024-2025 | Licart, Tirosint, Flector |
| Genentech USA, INC. | $37.19 | 2021 | |
| Novartis Pharmaceuticals Corporation | $31.87 | 2019-2020 | |
| Tolmar, INC. | $29.95 | 2023-2024 |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Mallinckrodt Hospital Products INC. | $29.44 | 2020 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $29.31 | 2024 | Xifaxan |
| Sunovion Pharmaceuticals INC. | $28.35 | 2020 | |
| Abbott Laboratories | $24.98 | 2024 | Infinity |
| Teva Pharmaceuticals USA, INC. | $22.85 | 2020 | |
| Corcept Therapeutics | $21.57 | 2025 | Korlym |
| Sanofi Pasteur INC. | $18.79 | 2019 | |
| Medtronic, INC. | $17.52 | 2021 | |
| Janssen Pharmaceuticals, INC | $17.38 | 2019 | |
| Echosens North America, INC. | $17.17 | 2022 | |
| Pfizer INC. | $11.00 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Schiano listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.